İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2021

Clinical research of insulin glargine U300 in type 1 diabetes mellitus patients with frequent hypoglycaemia: real-world experience

ARCHIVES OF MEDICAL SCIENCE - ATHEROSCLEROTIC DISEASES

YÖKSİS OpenAlex Açık erişim · diamond Atıf 3 Yüzdelik 44.8% FWCI 0.14
Yıl
2021
ISSN
2451-0629
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Introduction We aimed to see whether insulin glargine U300 can provide better blood glucose control while reducing hypoglycaemia in a more homogeneous population compared to previous studies. Material and methods The retrospective study included type 1 diabetes mellitus (T1DM) patients with frequent hypoglycaemia. For evaluation of fasting blood glucose, haemoglobin glycated (HbA1c) and weight at 6 months and 12 months (final), observation windows of 120–240 days (4–8 months) and 240–480 days (9–16 months) after insulin glargine U300 initiation, respectively, were permitted. Mean follow-up time was 12 months. Hypoglycaemia was defined as blood glucose level < 70 mg/dl, either symptomatic or asymptomatic, measured in hospital or at home. Results Forty-four patients were included in the study, and 35 patients completed the study – 20 (57.1%) females and 15 (42.9%) males, with a mean age of 24.1 ±6.6 years. Mean body mass index was 24.4 ±7.4 kg/m2. A significant decrease was not found between baseline and HbA1c values at 6 months (p = 0.199), but a significant decrease was found in the final period (between 9–16 months) (p = 0.025). Hypoglycaemic events occurred in all patients (100%) before using insulin glargine U300, while the incidence of hypoglycaemic events gradually decreased to 74.3%, 68.6%, and 68.6% between months 1–3, 3–6, and 6–9, respectively. Of the 26 patients who declared their level of satisfaction, 23 (88.5%) were satisfied, 2 (7.7%) indicated that there was no significant difference, and 1 (3.8%) patient was unsatisfied. Conclusions Over 9–16 months of follow-up, insulin glargine U300 led to a significant reduction not only of HbA1c levels but also of the frequency of hypoglycaemia, and also yielded high satisfaction rates.

Konular

  • Diabetes Management and Research
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Diabetes and associated disorders

Birincil konu Diabetes Management and Research

Yazarlar

  1. SAVAŞ VOLKAN KİŞİOĞLU
  2. AHMET SUAT DEMİR
  3. DAMLA TÜFEKÇİ
  4. YASEMİN EMÜR GÜNAY GİRESUN ÜNİVERSİTESİ
  5. HÜLYA ÇOŞKUN
  6. ÖZGE ÜÇÜNCÜ
  7. İRFAN NUHOĞLU
  8. MUSTAFA KOÇAK
  9. SERDAR KARAKULLUKÇU KARADENİZ TEKNİK ÜNİVERSİTESİ
  10. HALİL ÖNDER ERSÖZ